Member Info for PM2022

Well more appreciation for this cancer treating company from me. It will help save lives and we can only hope VAL grows and becomes more successful. I feel sorry for those trying to drag this company down. They will feel misery then complain when it suits them but yet opt to tarnish such companies.

A bigger and more successful company will serve a great purpose moving forward with a larger pipeline of drugs.

IAR why are you still here then if you don't believe in the strategy and the deal. TIme you moved like before pal and do something more constructive as you did earlier in the year,

The best part of the interview last night was when she spoke about women's health. She stated how the market is desperately searching for new preclinical drugs to take forward. I think 301 has a bright future and lots of research has been done with the Japanese and inhouse. Also if this breast cancer drug comes good it will be worth good money to be sold on.

Market cap when considering deal for 201 and our pipeline is extremely low. I can also see this being corrected.

Buy when others are fearful and sell when people are greedy. DYOR and watch the brilliant interview from last night.

So it doesn't get lost - Adams post after the interview from Last night and this morning. Elis you will get tired and get nowhere. GL.

RE: Blatant ramping on here03 Nov 2021 23:05

That's where you're wrong mate . As I've said numerous tines, it's actually a very, very, shrewd deal.

I've counted 15 "potential" indications for 201.

Make a start on 4, and you are actually looking at a Bayer/Astellas/Merck/AZ deal in milestones.

One of these makes it, and:

7% of a 500M drug per year is 35M/year; 7% of a 1000M drug is 70M/year revenue.

The more I think about it, the more I think they should have placed a self-imposed cap on themselves, to drive it home for those of the more hard of hearing disposition:

"Milestones and royalties will be capped at a maximum of 4 indications".

It really is a low-bar swing.

VALIRX CEO SUZY DILLY OUTLINES PLANS FOR 20104 Nov 2021 05:44

The Roast team talk candidly to AIM Listed ValiRx CEO Suzy Dilly about the recent letter of intent to Sub-License VAL 201 to TheoremRx Inc.

https://audioboom.com/posts/7973052-midweek-takeaway-with-valirx-ceo-suzy-dilly

RE: VALIRX CEO SUZ

One can only DYOR. Watch the interview for further information and make your own minds up as to whether you feel our market cap is very low at the moment.

https://audioboom.com/posts/7973052-midweek-takeaway-with-valirx-ceo-suzy-dilly

WCB you don't need to on this board. Not sure what you are doing here if you do zero research. Take that kid Ellis with you. Don't forget we was 20p for 9 months and not many thought we would get a deal.

We are undervalued due to false rumours and a lack of understanding of the US market. I see us rising over the coming days and weeks.

The risk here is very low compared to upside both short term and long term. That is how I roll and I see this as a brilliant investment.

I did like Adam's post this morning and what Suzy had stated last night. Not to mention all the other projects and potential licensing deals that will come through in the coming weeks/months. All for only 26 million market cap.

A peptide, with a convoluted patent profile, which has been developed primarily in prostate cancer, has gone to a team with a peptide expert, a patent agent, and a prostate cancer specialist.

Would never happen in big Pharma to get such a unique tie-up.

Yes - it's not a brand name, but that just increased the chances of 201 realising serious cash returns on investment, exponentially.

All IMO.

In a few years once the royalties kick in we should be £5-£10 range if it gets to market and with other deals. For now a fair price is 80p-100p IMO and more with further deals and news to come.

At this low market cap plenty of upside shorter or longer term. A brilliant CEO and company.

Market cap only 27 million. How low is that. Even at 60p it's only in 40 million which is nothing in pharma term.

Amazing upside here and what an interview. For those that missed it worth DYOR and watching it. Probably the best interview I have ever seen. Sign of big things to come if they have not done so already at current valuation.

I hope to click the buy button first. Hopefully a fantastic day ahead.

Clearly false information posted by certain gangs RNS day and false down. Brilliant value at current market cap as we all know.

A low risk high reward investment. That is how I like it here. Brilliant CEO and interview. Worth a watch.

Not to forget our strategy consists of low overheads and no wild placings or expensive in-house clinical trials like many other pharmas on AIM. Very confident we will see significant growth with projects coming through regularly to be sold on quickly and a potential deal for 301 and 401.

Also with the team in the US you would be confident 201 has a good chance to get to market and fast all will soon be priced in to an extent in the near future.

Works very differently in the US. This type of thing is very common. People here just seem to know about big names. It would have taken forever had we got AZ or one of the others to get to market not to mention problems with recruitment in the UK for larger trials. Suzy did mention she had a specialist in prostate cancer on board as well. They will be really motivated to take this forward fast and have the right market in the US to do this.

At the end of the day it is all relative to the current market cap. If we were 100-200 million already then I would think again about upside but given we are 25 million odd I see plenty of upside potential with no real downside. That is what investing is about considering risk vs reward. We also have a great CEO.

https://audioboom.com/posts/7973052-midweek-takeaway-with-valirx-ceo-suzy-dilly
If people think think they will get better elsewhere then best of luck.

Move on from Porky. He came back last time I see no reason at a market cap of 22 million why he would go anywhere else but that is his choice.

3-4 Uni tie ups a year,
fully funded
deal for 201 with royalties mid to high single digits which is excellent
Trials to take place in the US which is brilliant
Possible deals for 301 and 401
Numerous preclinical projects coming through to be sold for millions

It's all about our market cap and not how good a deal is. It is better than many of us think and as time goes on we will all notice that. The system works differently in the US. Besides relative to our market cap of only 22 million it is a strong buy for me.

Do listen to the interview to avoid being mislead by a few on here.

https://audioboom.com/posts/7973052-midweek-takeaway-with-valirx-ceo-suzy-dilly

We should also get official deal RNS in the coming weeks which should boost us more. Anything less than 80-100p is very cheap at the moment imo with potential for considerably more.

Best to DYOR and watch the interview. Be careful of the child Elis posting here.

Midweek Takeaway with ValiRx CEO Suzy Dilly

https://audioboom.com/posts/7973052-midweek-takeaway-with-valirx-ceo-suzy-dilly

24 market cap. Is that low or what and only 65 millions shares in issue.

Always consider upside vs potential downside when investing and here you need to ask with our pipeline and deal for 201 can we really stay below 24 million. I would have to say no but potential upside is massive here. I expect a significant correction to the SP to take place in the coming days.

I think Suzy is brilliant at doing interviews if she went to mainstream media VAL would do very well.

For those that have not seen the interview please do watch. It was simply brilliant.

Please share and tweet to everyone and spread the word. Plenty of opportunity to go around given the drop we had and how undervalued we currently are. About time we reached a decent level.

Ignore schoolboy Elis he needs to reported by everyone and action needs to be taken against this user who was party responsible for all those that lost money yesterday.

We should be 80-100p in my opinion. May not happen instantly but I can see us get to 55-60p then wait for the final contract then 80p plus. Further news we go up even more.

Suzy has a great company and pipeline which she is building even more and is trusted. Not main AIM companies that are better so why would we not be the best for everyone to invest in.

One of the best interviews ever. Also royalties mid to high single digits. Can see this rocket tomorrow and final contracts to be signed very soon in the coming weeks also RNS for that with plenty of time given for christmas.

Physiomics have a annual general meeting in 2-3 weeks it would not surprise me if we get an update regarding the work they have done. The contract also expires in the next week or two regarding all the work done. Some positive findings will boost us well.

Lots to look forward to this month all begins tonight with the live Q and A.

All good. They have enough working capital. We forget that the board are very confident of a second/ third deal plus preclinical projects to be sold on.

With larger potential milestones quicker route to market and royalties our market cap is very low. Hoping that we settle in the 80-100 p range soon.